Bristol-Myers Squibb to sell its HIV R&D portfolio to ViiV Healthcare
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has entered into two individual agreements with ViiV Healthcare, a global HIV company, to divest its pipeline of investigational HIV medicines consisting of a number of programs at different stages of discovery, preclinical and clinical development.
AstraZeneca enhances long-term growth through oncology investment in Acerta Pharma
- Details
- Category: AstraZeneca
AstraZeneca has entered into an agreement to invest in a majority equity stake in Acerta Pharma, a privately-owned biopharmaceutical company based in the Netherlands and US. The transaction provides AstraZeneca with a potential best-in-class irreversible oral Bruton's tyrosine kinase (BTK) inhibitor, acalabrutinib (ACP-196), currently in Phase III development for B-cell blood cancers and in Phase I/II clinical trials in multiple solid tumours.
Takeda announces sale of respiratory portfolio to AstraZeneca
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited (TOKYO:4502) has entered into a definitive agreement to sell its respiratory portfolio to AstraZeneca. In 2014 Takeda defined four therapeutic areas of focus: Gastroenterology, Oncology, Central Nervous System, and Cardiovascular and Metabolic.
AstraZeneca to strengthen therapy area franchise through acquisition of Takeda's respiratory business
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has entered into a definitive agreement to acquire the core respiratory business of Takeda Pharmaceutical Company Limited ("Takeda"). The deal will include the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).
Amgen reacquires all product rights to Prolia® (denosumab), XGEVA® (denosumab) and Vectibix® (panitumumab) from GSK in 48 countries
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) today announced that it has entered into a definitive agreement with GSK to reacquire all of its remaining rights to Prolia® (denosumab), XGEVA® (denosumab) and Vectibix® (panitumumab) in 48 countries in Asia, South America, Europe, Australia and other regions throughout the world.
Bristol-Myers Squibb and UCLA enter into a collaboration agreement
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced that they have entered into a collaboration agreement with UCLA as part of Bristol-Myers Squibb's Immuno-Oncology Rare Population Malignancy (I-O RPM) research program in the U.S.
Abbott and UC San Francisco discover new virus is linked to hepatitis C
- Details
- Category: Abbott
Abbott and University of California San Francisco (UCSF) published research identifying a newly discovered human virus, known as human pegivirus 2 (HPgV-2), and proving it is found among some patients with hepatitis C (HCV).
More Pharma News ...
- AstraZeneca to harness power of the Secretome and develop next-generation biologics in collaboration with new Wallenberg Centre for Protein Research
- Novo Nordisk and IBM partner to build diabetes care solutions on the Watson Health Cloud
- Shire partners with CrowdMed to offer US employees an innovative digital crowdsourcing diagnostic service
- 300 million child-friendly antimalarial treatments supplied without profit by Novartis
- AstraZeneca and Voluntis to test companion mobile app in ovarian cancer studies with the US National Cancer Institute
- Daratumumab combined with standard treatment for multiple myeloma produced deep and durable responses in relapsed or refractory patients
- GSK receives European marketing authorisation for Nucala® (mepolizumab) in 31 countries